50
Participants
Start Date
July 31, 2012
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Tenecteplase
Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
University of Calgary, Calgary
Collaborators (1)
Vancouver General Hospital
OTHER
Ottawa Hospital Research Institute
OTHER
Hopital Charles Lemoyne
OTHER
Université de Sherbrooke
OTHER
Vancouver Island Health Authority
OTHER
CHU de Quebec-Universite Laval
OTHER
University of Calgary
OTHER